Stablecoin Development CORP (NBY) — 8-K Filings

All 8-K filings from Stablecoin Development CORP. Browse 26 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (26)

Stablecoin Development Corp. Files 8-K on Financials — Apr 6, 2026 Risk: low
Stablecoin Development Corp. filed an 8-K on April 6, 2026, reporting results of operations and financial condition. The filing includes financial statements an
NovaBay Pharmaceuticals Files 8-K — Oct 22, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on October 22, 2025, reporting an event on October 16, 2025. The filing indicates "Other Events" and "Financial State
NovaBay Pharmaceuticals Files 8-K — Oct 21, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on October 21, 2025, reporting on events that occurred on October 20, 2025. The filing primarily concerns "Other Even
NovaBay Pharmaceuticals Files 8-K with Key Corporate Changes — Oct 20, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an 8-K on October 20, 2025, reporting events as of October 16, 2025. The filing indicates several key items including entry
NovaBay Pharmaceuticals Reports Board and Compensation Changes — Oct 9, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. announced on October 9, 2025, a change in its board of directors and executive compensation arrangements. The filing details the d
NovaBay Pharmaceuticals Files 8-K — Sep 18, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on September 18, 2025, to report current information. The filing does not contain specific financial details or mater
NovaBay Pharmaceuticals Files 8-K — Aug 26, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on August 26, 2025, reporting other events and financial statements. The filing does not contain specific details abo
NovaBay Pharmaceuticals Reports Material Events — Aug 19, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an 8-K on August 19, 2025, reporting several material events. These include entering into a definitive agreement, unregister
NovaBay Pharmaceuticals Submits Matters to Security Holders — Apr 22, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. filed an 8-K on April 22, 2025, reporting that on April 16, 2025, matters were submitted to a vote of its security holders. The fi
NovaBay Pharmaceuticals Enters Material Definitive Agreement — Mar 11, 2025 Risk: medium
On March 5, 2025, NovaBay Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with IRS number 680454536, f
NovaBay Pharma CFO Departs, Interim Appointed; New Directors Elected — Jan 22, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on January 15, 2025, the departure of its Chief Financial Officer, Mark J. Watson III. The company has appointed Dr. Jus
NovaBay Pharmaceuticals Completes Acquisition of 03 Life Sciences — Jan 10, 2025 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on January 3, 2025, the completion of its acquisition of 03 Life Sciences. The filing details the entry into a material
NovaBay Pharmaceuticals Files 8-K — Dec 19, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on December 19, 2024, reporting on matters submitted to a vote of security holders, other events, and financial state
NovaBay Pharmaceuticals Files 8-K on Shareholder Vote & Other Events — Nov 22, 2024 Risk: medium
On November 22, 2024, NovaBay Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security h
NovaBay Pharmaceuticals to be Acquired by Deerfield Management — Oct 16, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on October 16, 2024, that it has entered into a definitive agreement to be acquired by Deerfield Management Company, L.P
NovaBay Pharmaceuticals Enters Material Definitive Agreement — Sep 20, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on September 19, 2024, that it has entered into a Material Definitive Agreement. The company also disclosed costs associ
NovaBay Pharmaceuticals Files 8-K — Jul 29, 2024 Risk: medium
On July 26, 2024, NovaBay Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported other events and filed financial stateme
NovaBay Pharmaceuticals Files 8-K Report — Jul 11, 2024 Risk: low
On July 11, 2024, NovaBay Pharmaceuticals, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of op
NovaBay Pharmaceuticals Files 8-K — Jun 14, 2024 Risk: medium
On June 14, 2024, NovaBay Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securiti
NovaBay Pharmaceuticals Faces Delisting Notice — Jun 7, 2024 Risk: high
NovaBay Pharmaceuticals, Inc. filed an 8-K on June 7, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The earliest event r
NovaBay Pharmaceuticals Faces Delisting Concerns — May 29, 2024 Risk: high
NovaBay Pharmaceuticals, Inc. filed an 8-K on May 29, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The earliest event re
NovaBay Pharmaceuticals Files 8-K — Apr 22, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. filed an 8-K on April 22, 2024, to report other events and financial statements. The filing does not contain specific details abou
NovaBay Pharmaceuticals Faces Delisting Notice — Apr 19, 2024 Risk: high
NovaBay Pharmaceuticals, Inc. filed an 8-K on April 19, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is als
NovaBay Pharmaceuticals Files 8-K — Mar 25, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on March 24, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales
NovaBay Pharmaceuticals Files 8-K — Mar 14, 2024 Risk: medium
NovaBay Pharmaceuticals, Inc. announced on March 12, 2024, that it entered into a Material Definitive Agreement. The company also reported its results of operat
NovaBay Files 8-K on Material Agreement; Details Undisclosed — Jan 10, 2024
NovaBay Pharmaceuticals, Inc. filed an 8-K on January 10, 2024, reporting an event on January 5, 2024, related to an 'Entry into a Material Definitive Agreement

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX